4,588 results on '"Zannad, Faiez"'
Search Results
2. How to make cardiology clinical trials more inclusive
3. Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes
4. Integrating liver endpoints in clinical trials of cardiovascular and kidney disease
5. Consistency of HFrEF treatment effect in underrepresented groups in randomized clinical trials
6. Preclinical modeling of metabolic syndrome to study the pleiotropic effects of novel antidiabetic therapy independent of obesity
7. Relationship between NT-proBNP, echocardiographic abnormalities and functional status in patients with subclinical siabetic cardiomyopathy
8. The pan-PPAR agonist lanifibranor improves cardiometabolic health in patients with metabolic dysfunction-associated steatohepatitis
9. Characterizing diabetic cardiomyopathy: baseline results from the ARISE-HF trial
10. Clinical Correlates and Prognostic Impact of Cognitive Dysfunction in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF
11. Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Kidney Outcomes across Baseline Cardiovascular-Kidney-Metabolic Conditions: A Systematic Review and Meta-Analyses
12. Cardiovascular effects of rivaroxaban in heart failure patients with sinus rhythm and coronary disease with and without diabetes: a retrospective international cohort study from COMMANDER-HF.
13. Bridging Treatment Implementation Gaps in Patients With Heart Failure: JACC Focus Seminar 2/3.
14. Author Correction: Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes
15. The role of early-phase trials and real-world evidence in drug development
16. Urinary Marker Profiles in Heart Failure with Reduced Versus Preserved Ejection Fraction
17. Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF
18. Reaffirmation of Mechanistic Proteomic Signatures Accompanying SGLT2 Inhibition in Patients With Heart Failure: A Validation Cohort of the EMPEROR Program
19. Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis
20. From Cardiorenal Syndrome to Chronic Cardiovascular and Kidney Disorder: A Conceptual Transition
21. Chronic cardiovascular–kidney disorder: a new conceptual framework
22. Low Natriuretic Peptide Levels and Outcomes in Patients With Heart Failure and Preserved Ejection Fraction
23. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials
24. Racial Differences in Diabetic Cardiomyopathy: The ARISE-HF Trial
25. Randomized Trial of a Selective Aldose Reductase Inhibitor in Patients With Diabetic Cardiomyopathy
26. Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Impaired Renal Function
27. Cardiac Troponin and Treatment Effects of Omecamtiv Mecarbil: Results From the GALACTIC-HF Study
28. Pathophysiological Sex Differences in Heart Failure Progression After Acute Coronary Syndrome: Insights From the EXAMINE Trial
29. Circulating miR-133a-3p defines a low-risk subphenotype in patients with heart failure and central sleep apnea: a decision tree machine learning approach
30. Mineralocorticoid receptor antagonists
31. Neurohormonal activation in heart failure
32. Identification of endophenotypes supporting outcome prediction in hemodialysis patients based on mechanistic markers of statin treatment
33. Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis
34. Differential biomarker expression in heart failure patients with and without mitral regurgitation: Insights from BIOSTAT-CHF
35. Comparison of interleukin-6 and high-sensitivity C-reactive protein for cardiovascular risk assessment: Findings from the MESA study
36. Inflammation and remodeling pathways and risk of cardiovascular events in patients with ischemic heart failure and reduced ejection fraction
37. Author Correction: Chronic cardiovascular–kidney disorder: a new conceptual framework
38. The current best drug treatment for hypertensive heart failure with preserved ejection fraction
39. Effect of Finerenone on the KCCQ in Patients With HFmrEF/HFpEF: A Prespecified Analysis of FINEARTS-HF
40. Efficacy and Safety of Empagliflozin According to Background Diuretic Use in HFrEF: Post-Hoc Analysis of EMPEROR-Reduced
41. The Effect of Omecamtiv Mecarbil in Hospitalized Patients as Compared With Outpatients With HFrEF: An Analysis of GALACTIC-HF
42. Validation of the MEDIA echo score for the prognosis of heart failure with preserved ejection fraction
43. Polypharmacy and Optimization of Guideline-Directed Medical Therapy in Heart Failure: The GUIDE-IT Trial
44. Vascular Disease Burden, Outcomes and Benefits with Empagliflozin in Heart Failure: Insights From the EMPEROR-Reduced Trial
45. Underutilization of Mineralocorticoid Antagonists in Patients With Heart Failure With Reduced Ejection Fraction
46. Changes in health-related quality of life and treatment effects in chronic heart failure: a meta-analysis
47. Heart failure in obesity: insights from proteomics in patients treated with or without weight-loss surgery
48. Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved
49. Management of Worsening Heart Failure With Reduced Ejection Fraction: JACC Focus Seminar 3/3
50. Effect of Canagliflozin on Heart Failure Hospitalization in Diabetes According to Baseline Heart Failure Risk
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.